Healthcare: This Drug Pricing Scheme Cou...

We're moving over to a new show! Here's a sneak peek of what to expect when Motley Fool Money goes daily on January 5, 2022. Subscribe here on Spotify Subscribe here on Apple Podcasts 

Nick, Emily, Jason, and Dylan get together to talk through the companies they've learned the most from, the stocks they've sold recently (and why!) and also where you can catch all of them with The Motley Fool's new audio offering in 2022. Stocks: MELI, SHOP, GME, BBY Check out m ... Show More

In this last iteration of Industry Focus Consumer Goods (don’t worry - we’re just moving to Motley Fool Money!), Emily Flippen and Asit Sharma revisit their 2021 consumer goods basket as well as reflect on lessons learned from investing in the industry at large. Stocks: Grocery O ... Show More

If you had a rare disease and the only drug that could help you suddenly shot up in price how would you feel? What if your health service or insurer decided it was too expensive and they wouldn’t fund it any more? This is the problem facing some patients in the Netherlands.In ord ... Show More

<p>John Green recently made a video asking Johnson & Johnson not to extend their patent on a tuberculosis drug, which would keep it exclusive and expensive. Dr. Sydnee and Justin talk about how drug patents work, the recent (good) update about bedaquiline specifically, and the ne ... Show More

Parkinson’s patients derived more benefits from a salt solution they were told was an expensive drug than from the same solution when it was described as being cheap medication. Karen Hopkin reports 

It's hard to put a value on a human life. When you're well, perhaps you don't think about it. But if you're ill, getting access to the right drugs, whatever the cost, is a priority. But the NHS does not have a bottomless pit of money. And some medicines are judged too expensive t ... Show More

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ... Show More

Eli Lilly CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of New York, the head of the pharma giant says that they are looking to create an oral tablet i ... Show More

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More